The use of ivabradine for pharmacotherapy optimization

Evaluation of newly developed phenotyping probe in clinical practice was performed. Based on the results obtained, conclusion can be made, that ivabradine could be exploited as promising marker substrate in patients with compromised activity of CYP3A4 isoenzyme. It is also worth noting that metabolic «N-demethylivabradine/ivabradine» ratio could serve as a biomarker for pharmacotherapy optimization.